about
Hepatocellular carcinoma and the risk of occupational exposureHepatitis C virus: Promising discoveries and new treatmentsBiophysical Mode-of-Action and Selectivity Analysis of Allosteric Inhibitors of Hepatitis C Virus (HCV) Polymerase.Interferon-related genetic markers of necroinflammatory activity in chronic hepatitis CSilybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability.Viekira Pak Induced Fatal Lactic Acidosis: A Case Report of an Unusual Side EffectResveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance.No longer 'written off' - times have changed for the BBV-infected dental professional.Intrahepatic angiopoietin-2 correlates with chronic hepatitis C progression and is induced in hepatitis C virus replicon systems.Angiopoietin-2/angiopoietin-1 as non-invasive biomarker of cirrhosis in chronic hepatitis C.Implementation of the ECHO® telementoring model for the treatment of patients with hepatitis C.Sofosbuvir and daclatasvir.Evaluation of health status in patients with hepatitis c treated with and without interferon.Sofosbuvir Plus Daclatasvir in Treatment of Chronic Hepatitis C Genotype 4 Infection in a Cohort of Egyptian Patients: An Experiment the Size of Egyptian Village.Responsibility of hepatitis C virus in the development of hepatocellular carcinoma: From molecular alterations to possible solutions.Development of a Robust UPLC Method for Simultaneous Determination of a Novel Combination of Sofosbuvir and Daclatasvir in Human Plasma:
P2860
Q26750646-E2C8C362-0035-416A-A7BE-7232D9B87E2CQ27468916-FE029631-5175-4E35-88C5-EE4560C98B39Q32183060-12D0B6A8-E6CB-4DED-9550-CEA193EF931EQ33898567-77C4B1EE-81B1-404C-B787-E1D3119792B4Q36192046-33907F57-9991-47B3-B04C-A6CF47B1F4EDQ39043731-F67B817E-07CF-4EAB-ACBA-411E6B28C030Q40078355-D56C84E1-70B3-4A20-8FDB-CDCE4FEF61BCQ40373187-05EE8E00-F116-44B8-AEC3-12E977630CEAQ40405941-6A0B114D-868D-487A-B7FE-6F315B189465Q40428093-67DC47E5-707B-4DB2-A472-D74B8D4EB8E1Q40566363-C2B75819-688D-4A7B-A069-5EDB1FB99DFCQ42367744-8C8A957B-2626-4D3E-AD0F-A7A6B2DF5514Q47552347-75D3565B-6E3F-4694-A01C-312732807F47Q54964642-F313526C-6FC9-4DCD-923A-2013CEAAE530Q55465315-E1400DE0-9242-4CF8-92B5-A651AF1746DDQ58699240-324C10A6-D5D5-41DE-BA66-FA31C49C14C7
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Chronic hepatitis C: This and the new era of treatment
@ast
Chronic hepatitis C: This and the new era of treatment
@en
Chronic hepatitis C: This and the new era of treatment
@nl
type
label
Chronic hepatitis C: This and the new era of treatment
@ast
Chronic hepatitis C: This and the new era of treatment
@en
Chronic hepatitis C: This and the new era of treatment
@nl
prefLabel
Chronic hepatitis C: This and the new era of treatment
@ast
Chronic hepatitis C: This and the new era of treatment
@en
Chronic hepatitis C: This and the new era of treatment
@nl
P2093
P2860
P3181
P356
P1476
Chronic hepatitis C: This and the new era of treatment
@en
P2093
Adriana Toro
Annalisa Ardiri
Emanuele Bertino
Evelise Frazzetto
Gaetano Bertino
Giulia Malaguarnera
Giuseppe Rigano
Isidoro Di Carlo
Laura Scuderi
Maria Irene Ruggeri
P2860
P304
P3181
P356
10.4254/WJH.V8.I2.92
P407
P577
2016-01-01T00:00:00Z